Skip to main content

Table 2 DXR-MCI loss in the methotrexate plus adalimumab group and the MTX group stratified for disease activity measured by DAS28

From: Adalimumab reduces hand bone loss in rheumatoid arthritis independent of clinical response: Subanalysis of the PREMIER study

  Adalimumab + methotrexate Methotrexate
  N = 214 Median (mean) % DXR-MCI change N = 188 Median (mean) % DXR-MCI change
Remission
DAS28 ≤2.60
118 -2.43 (-2.73) 53 -2.15 (-3.03)
Low
disease activity
DAS28 2.61-3.20
36 -1.98 (-2.59) 30 -2.09 (-2.90)
Moderate
disease activity
DAS 28 3.21-5.10
51 -2.01 (-3.17) 81 -3.33 (-4.65)
High
disease activity
DAS28> 5.10
9 -1.63 (-2.72) 24 -3.02 (-4.64)
  1. DAS28 = 28-joint disease activity score; DXR = Digital X-ray radiogrammetry; MCI = metacarpal cortical index